10 GHP Biotechnology & Lifesciences Awards 2025 ased in Stevenage, VasoDynamics is a clinical stage pharmaceutical company dedicated to developing a portfolio of patient-friendly, cost-efficient treatments to prevent the debilitating and distressing complications of cancer therapies. At present, this trailblazing company’s first topical drugs are focused on targeting three common side effects of cancer treatments: an oral topical drug for Oral Mucositis caused by radiotherapy; a scalp topical drug for alopecia caused by chemotherapy; and a dermal topical drug for dermatitis caused by radiotherapy. VasoDynamics was founded in 2020 by Dr. Fiona Ningfeng Li, a trained Radiation Oncologist and Scientist with extensive research experience in tumour biology and carcinogenesis. During her clinical career, Fiona witnessed the debilitating and distressing side effects congruent with cancer treatments, sparking a steadfast and lifelong dedication to improving patient journeys and outcomes from cancer treatments through the prevention of such serious side effects. Behind Fiona is an experienced and diversified team whose innovation and dedication has earned the support from well-established and reputable financial, legal, and corporate governance firms. A young biotech company, VasoDynamics is driven by dynamic, seasoned professionals who share a commitment to the development of safe and effective medicines. To achieve this mission, the company fosters a culture of open discussion and input from both internal and external teams, vendors, and stakeholders. To retain such a high-performing team, Fiona told us that VasoDynamics maintains a strategic approach to its expansion. “Our robust hiring processes ensure that we select and retain team members with the appropriate experience, values, training, and Feb25228 B While lifesaving, cancer treatments can lead to severe and debilitating side effects. From oral mucositis to alopecia to dermatitis, these conditions not only impact physical health but also affect the emotional wellbeing and quality of life for patients, who are already navigating the emotional and physical toll of their diagnosis. Such side effects add layers of discomfort, stress, and frustration to an already difficult journey. VasoDynamics is a pioneering pharmaceutical development company focusing on creating therapies to mitigate these conditions and improve the quality of life for cancer patients. We heard more from Founder and CEO, Dr Fiona Ningfeng Li below. qualifications for their role,” she said. “Our staff receive ongoing support and training in accordance with their roles and experience, to ensure that VasoDynamics is aligned with the ever-evolving clinical research, commercial, and healthcare landscapes.” In such a rapidly advancing landscape, VasoDynamics distinguishes itself with its innovative product offering. Addressing an unmet clinical need, the company provides treatments for three common and severe side effects of cancer therapies for which no approved preventative pharmaceuticals currently exist. Its patient-friendly and cost-effective topical formulations are designed to reduce these side effects, enhancing patients’ quality of life by minimising hospitalisation and ensuring continuity in vital cancer treatments. These groundbreaking benefits position VasoDynamics as a beacon of innovation and ingenuity within the market. VasoDynamics has made significant strides in its clinical programmes. The company successfully completed its NG112 Phase Ib clinical trial in 2024, targeting the reduction and prevention of radiotherapy-induced Oral Mucositis. The clinical story report has been finalised, and the team presented their findings through research posters at the ESTRO Annual Meeting 2024 and MASCC Annual Conference 2024. Demonstrating its commitment to patient engagement and addressing diverse healthcare needs, VasoDynamics also participated in key events, including the Oncology Professional Care conference in London, the Head and Neck Cancer conference in Sheffield, and the Breast Cancer Symposium 2024 in London. Through the NG12-1 programme, focused on reducing severe radiodermatitis in radiotherapy patients, VasoDynamics is exploring managed access, supported by positive results from its Phase Ila trial in the USA. Significant progress has also been achieved in the NG13-2 programme, addressing chemotherapy-induced alopecia, with advancements in formulation optimisation and the futureproofing of its Investigational Medicinal Products supply chain. These clinical trials adhere to stringent global and national regulations, ensuring compliance through VasoDynamics’ robust quality systems and highly qualified teams. As for the future, VasoDynamics understands the need for an emerging, yet pioneering, company to remain adaptable and focused on its mission of directly addressing the unmet needs of patients undergoing cancer treatments. “Drug development poses many challenges, and success is contingent on many factors – some predictable and some not!” Fiona concluded. “Fundraising in the Life Sciences arena remains challenging, and this can be amplified for young biotech companies who must remain nimble, focused, and lean – especially in their early stages. “To realise and develop the full value of our products, VasoDynamics must address current clinical, health economic, and commercial requirements while exploring all channels to tackle underserved and unmet needs in the cancer care landscape.” Contact: Dr. Fiona Ningfeng Li Company: VasoDynamics Ltd Web Address: https://vasodynamics.co.uk/ Cancer Care Solutions Provider of the Year 2025 – UK
RkJQdWJsaXNoZXIy NTY1MjM3